about
Aspartame Intake Relates to Coronary Plaque Burden and Inflammatory Indices in Human Immunodeficiency VirusPrevalence and outcome of non-alcoholic fatty liver disease in adolescents and young adults undergoing weight loss surgery.Effects of recombinant human growth hormone (rhGH) administration on body composition and cardiovascular risk factors in obese adolescent girls.Visceral and subcutaneous adipose tissue FDG uptake by PET/CT in metabolically healthy obese subjects.Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies.Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trialFNDC5 relates to skeletal muscle IGF-I and mitochondrial function and gene expression in obese men with reduced growth hormoneAssociations between plasma branched-chain amino acids, β-aminoisobutyric acid and body composition.Metabolic Effects of Long-Term Reduction in Free Fatty Acids With Acipimox in Obesity: A Randomized TrialMetabolic effects of Roux-en-Y gastric bypass in obese adolescents and young adults.Comparing Outcomes of Two Types of Bariatric Surgery in an Adolescent Obese Population: Roux-en-Y Gastric Bypass vs. Sleeve Gastrectomy.The typology of metabolic syndrome in the transition to adulthood.Discordance of IGF-1 and GH stimulation testing for altered GH secretion in obesity.Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.Practical Review of Recognition and Management of Obesity and Lipohypertrophy in Human Immunodeficiency Virus Infection.Effects of Sodium Restriction on Activation of the Renin-Angiotensin-Aldosterone System and Immune Indices During HIV Infection.Differential relationships of hepatic and epicardial fat to body composition in HIVFibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.Insulin-like growth factor 1 inversely relates to monocyte/macrophage activation markers in HIV.Randomized, Placebo-Controlled Trial to Evaluate Effects of Eplerenone on Metabolic and Inflammatory Indices in HIV.Altered body composition, lipedema, and decreased bone density in individuals with Williams syndrome: A preliminary report.Unanticipated increases in hepatic steatosis among human immunodeficiency virus patients receiving mineralocorticoid receptor antagonist eplerenone for non-alcoholic fatty liver disease.Adrenoleukodystrophy: Guidance for Adrenal Surveillance in Males Identified by Newborn ScreenEndocrine Deficiency As a Function of Radiation Dose to the Hypothalamus and Pituitary in Pediatric and Young Adult Patients With Brain TumorsComparison of visceral fat measurement by dual-energy X-ray absorptiometry to computed tomography in HIV and non-HIVPhysical activity in adolescents and children and relationship to metabolic healthGlucose and lipid metabolism, bone density, and body composition in individuals with Williams syndromeTestosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral ClearanceEffects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical TrialImmune Correlates of Diffuse Myocardial Fibrosis and Diastolic Dysfunction Among Aging Women With Human Immunodeficiency VirusThe Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV
P50
Q33878675-75BCAE5A-DD43-4E69-AEE7-C2D8155280FDQ34175430-0CF4D403-1B6E-49D0-8DDE-A8B5575346FEQ34584665-C6350715-ABE6-4799-93F0-0DEB00C862B2Q35027669-6481581E-816C-490D-B681-76487DBE78E3Q35072510-A5C29516-8E61-43BB-91AD-1F6CA30F2AAEQ35186541-37F27E12-A209-409B-BFE8-222DD333FE70Q36473167-1BA18F24-E1A3-4DA9-85A9-85F30B0B36ECQ36686209-CD7E0D51-50D1-4AE8-B8EB-9151754B7142Q36716062-F32ACF4A-2C71-4F74-BC0C-82AA76B25943Q36798253-FBA8E486-0ECE-4DD7-B5FF-237964174E19Q37125002-5C69A42F-3E45-46AB-BCC2-93568750BFF8Q37616867-9F6A6C00-605C-4627-9F63-AA4B1F828569Q37624695-F41EFB5E-B21C-414A-895C-CEEEFEF587FDQ38612748-EDB0DCD8-BE7C-4FE1-A143-D0E861599B4EQ38741518-BD10FE7B-CE62-4B0C-8F80-0E002CEE3B80Q40567129-A2E8E19E-73E9-4DC5-8D02-312AC3A7936FQ42378087-4AC04006-E814-4B02-B1BD-5A62D799DDE0Q47795127-6598A248-3265-4702-B0FA-097316B02F03Q48504460-799C17C9-8E13-47FE-B71F-2F288ADDB582Q53695087-FC889DAA-839F-4AEF-AE3C-499595659FD5Q53829750-2BC14D2E-6181-45C4-8420-5117D793CE92Q53839507-BB6A1124-4DB2-42EC-A5B3-B3036911A6A8Q57028059-02F3F641-4C5D-4CD4-A014-0D19479D2597Q58767519-C45DE9A2-BC45-4925-9DE5-E76E9AF0FCC5Q64106247-70528A44-31F7-41D6-98D4-6FB13BA4397FQ90211796-A97AEB51-B985-43EB-BD06-2615E5872C4EQ90900965-81291C6C-7FB5-4F4A-A16B-1B3E112C8A5AQ91329522-88028E72-FADD-46FE-8609-D1C3E1881122Q91619205-3B542B0F-5F75-45A3-9778-58235EC8969AQ92113476-3BC19A0E-E849-4BAE-9DAE-36792F92378BQ93010026-690F44F1-C78A-4CE0-9EEB-DC0DC5FC921D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Takara L Stanley
@ast
Takara L Stanley
@en
Takara L Stanley
@es
Takara L Stanley
@nl
type
label
Takara L Stanley
@ast
Takara L Stanley
@en
Takara L Stanley
@es
Takara L Stanley
@nl
prefLabel
Takara L Stanley
@ast
Takara L Stanley
@en
Takara L Stanley
@es
Takara L Stanley
@nl
P106
P31
P496
0000-0002-2336-2958